Impact of new regulations on clinical trials in India

Authors

  • Vihang S. Chawan Department of Pharmacology, Topiwala National Medical College and B. Y. L. Nair Charitable Hospital, Mumbai Central, Mumbai-400008, Maharashtra
  • Kalpesh V. Gawand Department of Pharmacology, Topiwala National Medical College and B. Y. L. Nair Charitable Hospital, Mumbai Central, Mumbai-400008, Maharashtra
  • Abhishek M. Phatak Department of Pharmacology, Topiwala National Medical College and B. Y. L. Nair Charitable Hospital, Mumbai Central, Mumbai-400008, Maharashtra

DOI:

https://doi.org/10.18203/2349-3259.ijct20150592

Keywords:

Regulations, Approval, DCGI, Drug Controller General of India, Clinical Trial, India

Abstract

Background: India is one of the major destination for conducting clinical trials. The Drug Controller General of India (DCGI) is the governing body responsible for all pharmaceutical-research and regulatory issues in India. While conducting clinical trials in India, regulations have come to ensure safety and wellbeing of the study subjects in the trial. The present study was planned to see the number of trials approved by DCGI and their trend over the last 8 years in view of new regulatory guidelines.

Methods: Data obtained from website of the Regulatory Authority i.e. Central Drugs Standard Control Organization (CDSCO) regarding DGCI Approval of clinical trials from 2007 till 2014 are noted for analysis.

Results: Total 1799 Trials Approved. 2007 had lowest approvals with 3 clinical trials & 2010 being highest with 500 trial approvals. Mean ± SD Approval of 224.88 ± 172.46 with Median rate of 206 per year was observed. Trend of Trials approved by DCGI shows sharp peak around 2008-2010 which follows sharp fall around 2013.

Conclusion: The present study highlights the impact of these new regulations on Clinical Trials registered for approval of DCGI.

References

Kumar M, Kher S. Regulatory Considerations for Conducting Clinical Trials in India. Regulatory Affairs Focus. 2007;12(3):26-31.

Kumar M. Agencies Involved in Approving Clinical Trials in India. Regulatory Affairs Focus. 2007;12(8):34-9.

Kumar M, Tate K. Designing a Global Product Development strategy. Regulatory Affairs Focus. 2008;13(6):16-21.

Schedule – Y, Amendment version 2005, Drugs and Cosmetics Rules, 1945 Available online http://dbtbiosafety.nic.in/act/schedule_y.pdf. Accessed 7 May 2015.

Booming Clinical Trials Market in India, Market Research Reports, Marketing and Business Research, Industry Analysis. Available online http://www.marketsmonitor.com/Booming-Clinical-Trials-Market-in-India-Report/IM564.htm. Accessed 7 May 2015.

Ernst & Young/FICCI, The Glorious Metamorphosis: Compelling Reasons for Doing Clinical Research in India, September 2009, www.ficci.com/publication-page.asp?spid=20026

RNCOS, Booming Clinical Trials Market in India, September 2009, www.rncos.com/Report/IM564.htm. Accessed 7 May 2015.

Clinical Trials in India: Ethical Concerns. Bull WHO. 2008;86(8):581.

Srinivas S. Open House on Drug Trials: News on Social Justice and Development Issues in India. Infochange Health. Available online http://infochangeindia.org/20051110275/Health/Features/Open-house-on-drug-trials-in-India.html. Accessed 7 May 2015.

http://www.cdsco.nic.in/forms/SearchMore.aspx?Id=11 Accessed 7 May 2015.

http://www.cdsco.nic.in/forms/list.aspx?lid=2057&Id=31 Accessed 7 May, 2015.

http://www.cdsco.nic.in/writereaddata/notable%20achievements%20%282%29.pdf Accessed 7 May 2015.

http://www.cdsco.nic.in/forms/list.aspx?lid=1585&Id=1. Accessed 7 May 2015.

http://www.cdsco.nic.in/writereaddata/DCG%28I%29%20approved%20clinical%20trial%20registered%20in%20ctri%20website%20%28Jan.2013%29.pdf. Accessed 7 May 2015.

www.clinicaltrials.gov Accessed 7 May 2015.

Downloads

Published

2015-08-01

Issue

Section

Original Research Articles